Concord Drugs

Concord_Drugs26 Apr 2024

Pharmaceuticals

₹

-0.26 (-0.70%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Concord Drugs

Concord Drugs

Pharmaceuticals

Concord_Drugs26 Apr 2024

₹

-0.26 (-0.70%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
19-Mar-2024	BC	Appointment of Ms. Namratha Nagla (ACS-68979) as Company Secretary Cum Compliance Officer	19-Mar-2024
19-Mar-2024	BC	Appointment of Ms. Namratha Nagla (ACS-68979) as Company Secretary Cum Compliance Officer	19-Mar-2024
06-Feb-2024	BC	Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve Un-Audited financial results (Standalone and	13-Feb-2024
05-Jan-2024	BC	Trading members of the Exchange are hereby informed that the under mentioned new securities of Concord Drugs Limited (Scrip Code - 538965) are listed and permitted to trade on the Exchange with effec	08-Jan-2024
28-Dec-2023	BC	Trading members of the Exchange are hereby informed that the under mentioned new securities of Concord Drugs Limited (Scrip Code - 538965) are listed and permitted to trade on the Exchange with effec	29-Dec-2023

No Rights has been declared by Concord_Drugs

Book Closure

Record Date	Split Date	Purpose
19-Mar-2024	-	Appointment of Ms. Namratha Nagla (ACS-68979) as Company Secretary Cum Compliance Officer
19-Mar-2024	-	Appointment of Ms. Namratha Nagla (ACS-68979) as Company Secretary Cum Compliance Officer
13-Feb-2024	-	Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve Un-Audited financial results (Standalone and
08-Jan-2024	-	Trading members of the Exchange are hereby informed that the under mentioned new securities of Concord Drugs Limited (Scrip Code - 538965) are listed and permitted to trade on the Exchange with effec
29-Dec-2023	-	Trading members of the Exchange are hereby informed that the under mentioned new securities of Concord Drugs Limited (Scrip Code - 538965) are listed and permitted to trade on the Exchange with effec

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Concord Drugs Ltd ₹36.62(-0.26/-0.70%)	36.62	-0.26	36.62	28.04	43.60	1.03
Astrazeneca Pharma India Ltd ₹5,415.40(+81.55/1.53%)	5,415.40	+81.55	13,538.50	71.09	84.88	20.67
Bliss GVS Pharma Ltd ₹122.60(+5.85/5.01%)	122.60	+5.85	1,283.51	60.79	18.80	1.31
Cipla Ltd ₹1,409.40(+4.00/0.28%)	1,409.40	+4.00	113,794.25	54.54	34.60	4.40
Abbott India Ltd ₹25,864.85(+201.35/0.78%)	25,864.85	+201.35	54,962.81	15.87	47.98	17.68
Amrutanjan Health Care Ltd ₹680.85(-8.80/-1.28%)	680.85	-8.80	1,968.38	13.21	44.73	7.51

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	12.62	7.38	8.79	11.54	13.53	13.72
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	12.62	7.38	8.79	11.54	13.53	13.72
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	0.00	0.01	0.00	0.00	0.00	0.00
Total Income	12.62	7.39	8.79	11.54	13.53	13.72
Total Expenditure	12.06	5.85	7.39	10.80	12.08	12.53
PBIDT	0.56	1.54	1.40	0.74	1.44	1.19
Interest	0.43	0.39	0.39	0.42	0.45	0.42
PBDT	0.13	1.15	1.01	0.32	1.00	0.77
Depreciation	0.38	0.38	0.38	0.31	0.38	0.53
Tax	0.00	0.25	0.18	0.02	0.17	0.09
Deferred Tax	-0.01	-0.01	-0.03	-0.08	-0.01	-0.03
Reported Profit After Tax	-0.24	0.53	0.49	0.07	0.45	0.18
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	-0.24	0.53	0.49	0.07	0.45	0.18

EPS (Unit Curr.)	-0.24	0.56	0.52	0.07	0.52	0.21
EPS (Adj) (Unit Curr.)	-0.24	0.56	0.52	0.07	0.52	0.21
Calculated EPS (Unit Curr.)	-0.24	0.56	0.52	0.07	0.52	0.21
Calculated EPS (Adj) (Unit Curr.)	-0.24	0.56	0.52	0.07	0.52	0.21
Calculated EPS (Ann.) (Unit Curr.)	-0.96	2.26	2.09	0.30	2.08	0.83
Calculated EPS (Adj) (Ann.) (Unit Curr.)	-0.96	2.26	2.09	0.30	2.08	0.83
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	10.00	9.32	9.32	9.32	8.74	8.74
Reserve & Surplus	24.17	23.83	22.88	22.39	21.48	19.99
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	4.44	20.87	15.93	6.41	10.64	8.67
PBDTM(%)	1.03	15.58	11.49	2.77	7.39	5.61
PATM(%)	-1.90	7.18	5.57	0.61	3.33	1.31

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	12.78	7.52	8.98	12.31	13.53	13.72
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	12.78	7.52	8.98	12.31	13.53	13.72
Other Operating Income	0.00	0.01	0.00	0.00	0.00	0.00
Other Income	0.00	0.00	0.00	0.00	0.00	0.00
Total Income	12.78	7.52	8.98	12.31	13.53	13.72
Total Expenditure	12.15	5.91	7.52	11.34	12.08	12.53
PBIDT	0.63	1.61	1.46	0.97	1.44	1.19
Interest	0.50	0.43	0.44	0.50	0.45	0.42
PBDT	0.13	1.19	1.02	0.47	1.00	0.77
Depreciation	0.39	0.39	0.38	0.33	0.38	0.53
Minority Interest Before NP	0.00	0.00	0.00	0.00	0.00	0.00
Tax	0.00	0.25	0.18	0.05	0.17	0.09
Deferred Tax	-0.01	-0.01	-0.03	-0.08	-0.01	-0.03
Reported Profit After Tax	-0.24	0.56	0.49	0.16	0.45	0.18
Minority Interest After NP	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit after Minority Interest	-0.24	0.56	0.49	0.16	0.45	0.18

Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	-0.24	0.56	0.49	0.16	0.45	0.18

EPS (Unit Curr.)	-0.24	0.60	0.53	0.17	0.52	0.21
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	10.00	9.32	9.32	9.32	8.74	8.74

Public Shareholding (Number)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (%)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	4.93	21.41	16.26	7.88	10.64	8.67
PBDTM(%)	1.02	15.82	11.36	3.82	7.39	5.61
PATM(%)	-1.88	7.45	5.46	1.30	3.33	1.31

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	9.32	8.74	8.74	8.74	7.86	7.86
Reserves Total	21.83	19.62	18.02	14.74	15.29	11.46
Equity Share Warrants	0.56	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	31.71	28.36	26.76	23.48	23.15	19.32
Secured Loans	15.63	16.43	12.96	9.35	9.80	12.70
Unsecured Loans	0.00	0.00	0.01	0.22	0.03	0.92
Total Debt	15.63	16.43	12.97	9.57	9.83	13.62
Total Liabilities	47.34	44.79	39.73	33.05	32.98	32.94
APPLICATION OF FUNDS :
Gross Block	37.61	37.12	35.22	30.98	30.84	30.79
Less : Accumulated Depreciation	24.75	23.15	21.39	20.46	18.99	17.28
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	12.86	13.97	13.83	10.52	11.85	13.51
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	0.92	0.55	0.00	1.00	0.29	0.00
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	1.42	0.00	0.00	0.00	0.00	0.00
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	17.50	17.49	11.87	16.43	18.64	18.62
Sundry Debtors	16.35	22.86	20.73	25.45	48.43	71.17
Cash and Bank	0.10	0.07	0.06	0.04	0.18	0.06
Loans and Advances	7.45	1.48	3.37	3.65	2.48	2.17
Total Current Assets	41.40	41.89	36.03	45.56	69.74	92.02
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	5.95	8.24	6.54	22.16	46.82	70.12
Provisions	0.35	0.67	0.47	0.12	0.12	0.38
Total Current Liabilities	6.30	8.91	7.01	22.28	46.94	70.50
Net Current Assets	35.11	32.98	29.02	23.28	22.80	21.52
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Liability	0.54	0.66	0.68	0.14	0.13	0.21
Net Deferred Tax	-0.54	-0.66	-0.68	-0.14	-0.13	-0.21
Total Assets	49.77	46.84	42.17	34.66	34.81	34.82
Contingent Liabilities	0.00	0.00	0.00	0.00	0.00	0.00

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	0.04	0.04	0.01	0.16	0.04
Net Cash from Operating Activities	2.24	0.77	1.62	2.48	1.19
Net Cash Used In Investing Activities	-2.27	-2.44	-3.67	-0.84	-0.34
Net Cash Used In Financing Activities	0.05	1.68	2.07	-1.79	-0.73
Net Inc./Dec In Cash And Cash Equivalents	0.03	0.01	0.02	-0.15	0.12
Cash And Cash Equivalents At End Of The Year	0.08	0.04	0.04	0.01	0.16

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

55.41%

FII Shareholding

0.00%

DII Shareholding

0.00%

Public Shareholding

44.59%

**Promoter pledged shareholding 55.41%

About Concord Drugs Ltd

Concord Drugs Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 36.62 crores. It has reported a sales of Rs. 12.62 crores and a net profit of Rs. -0.24 crores for the quarter ended December 2018. The company management includes S Nagi Reddy, S Nagi Reddy,K Ramchandra Reddy,Koni Reddy,S. Nagavenkata Hareesh,S. Manoj Kumar Reddy,Summela Kasu,Namratha Nagla (Concord Drugs Ltd) among others.

Chairman

S Nagi Reddy

Registered office

Survey No 249 Brahmanapally V,Hayathnagar M,Ranga Reddy,Telangana,501511

FAX :

Background

Incorporation Year1995

Face Value₹10

Market Lot1

How to buy Concord Drugs shares on nse?

To buy Concord Drugs shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Concord Drugs share price today?

The Concord Drugs shares price on nse is Rs.36.62 today.

What is the market cap of Concord Drugs shares on BSE ?

The company has a market capitalization of Rs.36.62Cr

What is the PE & PB ratio of Concord Drugs shares ?

PE is 43.6 and PB is 1.03

What is the 52 Week High and Low of Concord Drugs shares?

Concord Drugs stock price high: Rs.61.5 Concord Drugs stock price low: Rs.25.56